Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3423556 | 0.87 | CTBP2 (0.44) | — | |
| SCHEMBL6669579 | 0.81 | EGFR (0.53) | EGFRERBB2KDM4EHCAR2SIGMAR1 | |
| SCHEMBL7134071 | 0.81 | TAAR1 (0.48) | EGFRERBB2HCAR2SIGMAR1TAAR1 | |
| SCHEMBL6047068 | 0.81 | THRB (0.33) | EGFRERBB2KDM4ENPC1RAB9A | |
| SCHEMBL78652 | 0.81 | AKR1B1 (0.58) | EGFRERBB2KDM4EHCAR2SIGMAR1 | |
| SCHEMBL8215471 | 0.80 | EGFR (0.46) | EGFRERBB2KDM4ETAAR1MAPK8 | |
| SCHEMBL19656181 | 0.80 | TAAR1 (0.46) | HCAR2TAAR1FFAR1FFAR4NPC1 | |
| SCHEMBL1137221 | 0.80 | CTBP2 (0.60) | KDM4ESIGMAR1TAAR1IDO1 | |
| Hydrochloric Acid SCHEMBL1374336 | 0.79 | AKR1B1 (0.56) | EGFRERBB2KDM4EHCAR2SIGMAR1 | |
| Methane SCHEMBL10697726 | 0.79 | AKR1B1 (0.56) | EGFRERBB2KDM4EHCAR2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815935-B2 | Inhibitors of protein prenyltransferases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130102639-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-04-25 | — | — | US | disclosed |
| US-8101665-B2 | Process for synthesis of tritiated and deuterated thiorphan and acetorphan | ROCHE PALO ALTO LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101665-B2 | Process for synthesis of tritiated and deuterated thiorphan and acetorphan | ROCHE PALO ALTO LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101665-B2 | Process for synthesis of tritiated and deuterated thiorphan and acetorphan | ROCHE PALO ALTO LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | ROCHE PALO ALTO LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | ROCHE PALO ALTO LLC | 2011-12-29 | — | — | US | disclosed |
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | ROCHE PALO ALTO LLC | 2011-12-29 | — | — | US | disclosed |
| CN-102174017-A | Pyrazolyl derivatives in the form of drugs for treating acute or chronic neuronal regressions | AVENTIS PHARMA SA | 2011-09-07 | — | — | CN | disclosed |
| US-20110178138-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2009077386-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077386-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| CN-1906172-A | Pyrazole derivatives as medicaments for the treatment of acute or chronic neuronal degeneration | AVENTIS PHARMA SA (FR) | 2007-01-31 | — | — | CN | disclosed |
| EP-0888341-B1 | NOVEL SULPHUR DERIVATIVES COMPRISING AN AMIDE BOND, METHOD FOR PREPARING SAME, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH DERIVATIVES | AVENTIS PHARMA SA (FR) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | NAT1, ZRANB2, TXN | EGFR 2255/4885ERBB2 3082/4885KDM4E 4066/4885 |
| US-20130102639-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | RABGGTA, FNTA, RABGGTB | EGFR 3525/4885ERBB2 3814/4885KDM4E 2985/4885 |
| US-20110178138-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | RABGGTA, FNTA, RABGGTB | EGFR 3525/4885ERBB2 3814/4885KDM4E 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.